What research findings exist for SS-31 regarding mitochondrial function, muscle capacity, and fatigue?
Improves overall skeletal muscle and some single-fiber contraction indicators. Additionally, research reports: improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42290373 | HFpEF rats; 12-week intervention | Improves overall skeletal muscle and some single-fiber contraction indicators. | Disease animal models cannot be extrapolated to improved exercise performance in healthy humans. |
| 2025 · PMID 40080911 | Aged C57BL/6J mice; 8-week elamipretide treatment | Improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty. | No significant reversal of epigenetic or transcriptional age was detected; cannot promote reversing biological age; not equivalent to effects in healthy humans. |
| 2024 · PMID 38602181 | Barth syndrome patients; TAZPOWER up to 168 weeks open-label extension | Walking distance, fatigue, and some cardiac indicators improved relative to the baseline of the open-label extension period. | Only 10 patients entered the extension phase, while 8 completed it; There was no placebo comparison during the extension period, and fatigue resistance was not extrapolated to ordinary people. |
References
How does skeletal muscle performance change in diseased rats?
Improves overall skeletal muscle and some single-fiber contraction indicators.[1] ↗
HFpEF rats; 12-week intervention
Disease animal models cannot be extrapolated to improved exercise performance in healthy humans.
View the Article Title and Full Citation＋
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure · Volume and issue year 2026
First published 2026-06-15 · PMID 42290373
DOI 10.1161/CIRCHEARTFAILURE.126.014397
What does the anti-fatigue research in aged mice indicate?
Improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty.[2] ↗
Aged C57BL/6J mice; 8-week elamipretide treatment
No significant reversal of epigenetic or transcriptional age was detected; cannot promote reversing biological age; not equivalent to effects in healthy humans.
View the Article Title and Full Citation＋
The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age.
Aging Cell · Volume and Year 2025
First published 2025-03-13 · PMID 40080911
DOI 10.1111/acel.70026
What was observed in the long-term follow-up of Barth syndrome?
Walking distance, fatigue, and some cardiac indicators improved relative to the baseline of the open-label extension period.[3] ↗
Barth syndrome patients; TAZPOWER up to 168 weeks open-label extension
Only 10 patients entered the extension phase, while 8 completed it; There was no placebo comparison during the extension period, and fatigue resistance was not extrapolated to ordinary people.
View the Article Title and Full Citation＋
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Genetics in Medicine: official journal of the American College of Medical Genetics · Volume, Issue, Year 2024
First published 2024-04-08 · PMID 38602181
DOI 10.1016/j.gim.2024.101138
Common issues and corresponding evidence
What research findings exist for SS-31 regarding mitochondrial function, muscle capacity, and fatigue?＋
Improves overall skeletal muscle and some single-fiber contraction indicators. Additionally, research reports: improves muscle anti-fatigue capacity and some cardiac functions, and slows the accumulation of frailty.[1] ↗ [2] ↗
What population is the anti-fatigue data for SS-31 derived from?＋
Human long-term data from small Barth syndrome population; other muscle performance studies included aged mice and disease rats. Cannot promise anti-fatigue effects in general healthy people based on this.[3] ↗ [2] ↗ [1] ↗
SS-31—these conclusions apply to which study populations?＋
HFpEF rats; 12-week intervention; aged C57BL/6J mice; 8-week elamipretide treatment; Barth syndrome patients; TAZPOWER maximum 168-week open-label extension. Disease animal models cannot be extrapolated to improved exercise performance in healthy humans.[1] ↗ [2] ↗ [3] ↗
SS-31
Return to catalog specifications and batch file verification entry.
